Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer
- PMID: 31453359
- PMCID: PMC6696850
- DOI: 10.1177/2381468319852594
Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer
Abstract
Background. Treatment options in oncology are rapidly advancing, and public payer systems are increasingly under pressure to adopt new but expensive cancer treatments. Cost-utility analyses (CUAs) are used to estimate the relative costs and effects of competing interventions, where health outcomes are measured using quality-adjusted life years (QALYs). Health state utility values (HSUVs) are used to reflect health-related quality of life or health status in the calculation of QALYs. To support reimbursement agencies in the appraisal of oncology drug submissions, which typically include a CUA component, we have proposed a systematic literature review of published HSUV estimates in the field of oncology. Methods. The following databases will be searched: MEDLINE, EMBASE, EconLit, and CINAHL. A team of reviewers, working independently and in duplicate, will evaluate abstracts and full-text publications for eligibility against broad inclusion criteria. Studies using a direct, indirect, or combination approach to eliciting preferences related to cancer or cancer treatments are eligible. Data extraction will capture details of study methodology, participants, health states, and corresponding HSUVs. We will summarize our findings with descriptive analyses at this stage. A pilot review in thyroid cancer is presented to illustrate the proposed methods. Discussion. This systematic review will generate a comprehensive summary of the oncology HSUV literature. As a component of the Health Utility Book (HUB) project, we anticipate that this work will assist both health economic modelers as well as critical reviewers in the development and appraisal of CUAs in oncology.
Keywords: health state utility values; medical oncology; systematic review.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB).Med Decis Making. 2019 May;39(4):370-378. doi: 10.1177/0272989X19837969. Epub 2019 Mar 22. Med Decis Making. 2019. PMID: 30902030
-
Health state utility values among children and adolescents with disabilities: protocol for a systematic review.BMJ Open. 2018 Feb 21;8(2):e019978. doi: 10.1136/bmjopen-2017-019978. BMJ Open. 2018. PMID: 29467137 Free PMC article.
-
Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses.Breast Cancer Res Treat. 2017 Aug;164(3):527-536. doi: 10.1007/s10549-017-4283-8. Epub 2017 May 11. Breast Cancer Res Treat. 2017. PMID: 28497177 Review.
-
Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.Appl Health Econ Health Policy. 2021 Jan;19(1):29-44. doi: 10.1007/s40258-020-00600-w. Appl Health Econ Health Policy. 2021. PMID: 32661846
-
Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis.Value Health. 2020 Sep;23(9):1256-1267. doi: 10.1016/j.jval.2020.05.014. Epub 2020 Aug 1. Value Health. 2020. PMID: 32940244
Cited by
-
A Systematic Literature Review of Health Utility Values in Breast Cancer.Med Decis Making. 2022 Jul;42(5):704-719. doi: 10.1177/0272989X211065471. Epub 2022 Jan 18. Med Decis Making. 2022. PMID: 35042379 Free PMC article.
References
-
- Canadian Agency for Drugs and Technology in Health. CADTH Common Drug Review. Submission Guidelines for the CADTH Common Drug Review. Ottawa: Canadian Agency for Drugs and Technology in Health; 2014.
-
- Department of Health, Commonwealth of Australia. Procedure Guidance for Listing Medicines on the Pharmaceutical Benefits Scheme. Canberra: Department of Health, Commonwealth of Australia; 2018.
-
- National Institute for Health and Care Excellence. Developing NICE Guidelines: The Manual. London: National Institute for Health and Care Excellence; 2014. - PubMed
-
- Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716–21. - PubMed
-
- Blinman P, King M, Norman R, Viney R, Stockler MR. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol. 2012;23(5):1104–10. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials